Valcare Medical is a clinical-stage medtech company developing transcatheter solutions for mitral valve disease. Its platform is designed to replicate key aspects of surgical repair through minimally invasive procedures, addressing a significant unmet need in cardiovascular care.
What Valcare Medical does
Valcare Medical is a clinical-stage company focused on transcatheter solutions for mitral regurgitation, a condition that remains underdiagnosed and undertreated at scale. The company has developed the AMEND™ Transcatheter Mitral Valve Repair Annuloplasty System, designed to reproduce the anatomical remodelling achieved through surgical annuloplasty using a minimally invasive approach.
The system is delivered via a transseptal procedure and is intended to reduce procedural complexity compared to open-heart surgery. Its design also aims to preserve future treatment options for patients, an important consideration in structural heart interventions.
The company is advancing its clinical development programme and has reported initial procedural milestones in the United States as part of its early feasibility studies. In parallel, Valcare continues to strengthen its leadership and governance structure with experienced executives from the medical device sector.
Why Elemento partnered with Valcare Medical
Elemento’s alignment with Valcare Medical reflects a broader conviction in the continued evolution of the structural heart market. The company’s approach builds on an established surgical principle, adapting it to a less invasive delivery method that may expand access to treatment for higher-risk patient populations.
The collaboration is driven by the opportunity to support a clinically grounded technology, an experienced team, and a pathway that addresses a significant unmet medical need. Valcare’s progress in early clinical validation and its ongoing development journey create a context for long-term partnership and shared value creation.
